Confirmed a studyThe role of the biomarker of estrogen receptors in local ductal cancer, conducted by Queen Mary University researchers in London and published in the Journal of Clinical Cancer Research, provides a new and more accurate method for predicting the long-term outcomes of this pre-operative stage of breast cancer.
The estrogen receptor
The new research confirms the role of the estrogen receptor in predicting long-term outcomes in DCIS. The authors present a new, more accurate method for assessing the future in predicting long-term outcomes in DCIS.
This is the first study to use samples from a randomized trial to investigate the estrogen receptor as a predictive marker in DCIS. The researchers found that the receptor is a strong predictive factor with a greater than 3-fold risk of a similar recurrence in the negative “estrogen” receptor for DCIS, and then concluded that the estrogen receptor should be routinely evaluated in DCIS, and that the clonal method that they report should be considered. about her.
Power of results
“It is unlikely that such a study is currently being reproduced elsewhere,” said lead author Manjish Thurat of Queen Mary University. The strength of these results means that we can rely on them to make changes to clinical practice. ” He added, “Routine tests of the estrogen receptor” in DCIS will help avoid both overtreatment.
“It is very difficult at present to determine whether DCIS will develop into invasive breast cancer, which means that thousands of people will undergo unnecessary and intensive treatment,” said Michael Mitchell, chief executive of Cancer Research UK. “This research shows that we may be able in the future to ensure that patients receive appropriate care, which may save many people from undergoing cancer treatment that requires physical and mental effort.”